Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD
12:47pm, Monday, 11'th Dec 2023
bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
bluebird bio faces challenges despite sickle cell therapy approval
09:41am, Monday, 11'th Dec 2023
bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reactions have been mixed. Despite the FDA greenlight, BLUE shares experienc
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease
01:10pm, Friday, 08'th Dec 2023
CNBC's Angelica Peebles reports on the latest news in bioscience.
US approves two gene therapies for sickle cell disease
11:21am, Friday, 08'th Dec 2023
The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.
Bluebird Stock Upgraded Ahead of Anticipated FDA Approval
10:47am, Friday, 08'th Dec 2023
Bluebird Bio Inc (NASDAQ:BLUE) stock is enjoying a boost today, after an upgrade from Morgan Stanley to "equal-weight" from "underweight," with a price-target hike to $7.00 from $3.00.
These 2 Stocks Could Be About to Soar: Are They Buys?
08:45am, Thursday, 07'th Dec 2023
Madrigal aims to offer a treatment in an area where success has eluded many peers. Bluebird Bio is closing in on its third U.S. approval for a gene-editing therapy.
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
09:01am, Friday, 01'st Dec 2023
bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.
Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
06:37pm, Wednesday, 29'th Nov 2023
bluebird bio specializes in gene therapies for severe genetic diseases and has two FDA-approved products. The company has a PDUFA date of December 20 for the approval of lovo-cel for sickle cell disea
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
02:28pm, Wednesday, 29'th Nov 2023
Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2 Biotech Stocks That Could Soar in December
04:44pm, Sunday, 26'th Nov 2023
Biotech stocks with major catalysts can be powerful capital appreciation vehicles. Bluebird Bio and Structure Therapeutics both have significant events scheduled for next month.
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
05:18pm, Tuesday, 07'th Nov 2023
The biotech unveiled its latest set of quarterly figures. With two recently commercialized medicines, its revenue leaped significantly higher on a year-over-year basis.
bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
01:32pm, Tuesday, 07'th Nov 2023
bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene aut
bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript
11:18am, Tuesday, 07'th Nov 2023
bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript
Is Bluebird Bio Stock a Buy?
08:45am, Saturday, 04'th Nov 2023
Bluebird Bio has experienced a barrage of issues in the past five years. The biotech has a potential approval on the way that could help it rebound.
7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%
11:32am, Thursday, 02'nd Nov 2023
The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.
